dmo, I wish I can tell you its a super secret strategy but its not. I follow the companies like any other. I read up on their drug, listen to their conference call, look at their pipeline, read their top analyst assessment, analyze their stock chart, read counter views, cross-ex their data with known publish studies of similiar drug or class of drug. In the end, you put all of it together and try to make your best estimation and make a buck or two from it. On rare occassion you hit a homerun but most of the time in Biotech you take small profit and run!